RecruitingNCT06070961
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Michele Merli, MDU.O.C Ematologia, Ospedale di Circolo, Varese
- Intervention
- Cellular immunity vs SARS-CoV-2(diagnostic_test)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (14)
- Azienda Ospedaliera S.Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico, Avellino, AV, Italy
- A.O. SS. Antonio e Biagio e Cesare Arrigo, S.C. Ematologia, Alessandria, IT, Italy
- Nuovo Ospedale degli Infermi, SSD Ematologia, Biella, IT, Italy
- ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Milan, IT, Italy
- Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - Ematologia, Milan, IT, Italy
- A.O.U. Maggiore della Carità di Novara - S.C.D.U. Ematologia, Novara, IT, Italy
- IRCCS Policlinico San Matteo - Divisione di Ematologia, Pavia, IT, Italy
- Ospedale Guglielmo da Saliceto - U.O. Ematologia, Piacenza, IT, Italy
- A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U, Torino, IT, Italy
- A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia, Torino, IT, Italy
- ASST Spedali Civili - S.C. Ematologia, Brescia, Italy
- Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia, Florence, Italy
- Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia, Reggio Emilia, Italy
- A.O.U. Senese - U.O.C. Ematologia, Siena, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06070961 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca